New immunisation reference page: Yellow fever
Yellow fever is an acute viral haemorrhagic disease transmitted by infected mosquitos. It occurs in the tropical and subtropical regions of Africa, the Caribbean and Central/South America. Vaccination against yellow fever is a requirement for travel to and from certain countries. For more information, including how to access a yellow fever vaccination, please view our reference page below:
MVEC Vodcast series - COVID-19 vaccines
जैसा कि 2020 करीब आ रहा है, आशावाद है कि SARS-CoV-2 (COVID-19) के लिए एक सुरक्षित और प्रभावी टीका जल्द ही महामारी को नियंत्रित करने के लिए अनुमोदित किया जाएगा। दुनिया भर में 200 से अधिक वैक्सीन उम्मीदवार वर्तमान में नैदानिक परीक्षणों के विभिन्न चरणों में हैं, ऑस्ट्रेलिया ने 4 अलग-अलग टीकों के साथ अग्रिम खरीद समझौतों पर हस्ताक्षर किए हैं।
हमारी 3-भाग वाली वोडकास्ट श्रृंखला में, COVID-19 टीके, डॉ. डेरिल चेंग और डॉ. डेनिएला साय चर्चा करते हैं कि इतनी कम समयावधि में एक टीका विकसित करना कैसे संभव है, नैदानिक परीक्षणों में उपयोग किए जा रहे विभिन्न वैक्सीन प्लेटफॉर्म और उनके व्यक्तिगत फायदे और नुकसान , साथ ही विभिन्न प्राथमिकता समूहों को टीकाकरण की पेशकश की जाएगी। डेरिल और डेनिएला क्लिनिकल परीक्षणों के प्रारंभिक परिणामों पर स्पर्श करते हैं और वे हमें टीके की सुरक्षा और प्रभावशीलता के संदर्भ में दिखाते हैं, साथ ही चल रही सुरक्षा निगरानी पर भी चर्चा करते हैं जो एक बार उपयोग के लिए एक वैक्सीन को मंजूरी दे दी जाती है।
You can view the vodcasts via the link below:
TGA COVID-19 resource hub
The Therapeutic Goods Administration (TGA) have developed a dedicated COVID-19 resource hub to host information for consumers, health care professionals and sponsors. This hub details the COVID-19 vaccine approval process for Australia, common questions relating to COVID-19 vaccine safety, quality and effectiveness, as well as the regulatory processes and requirements.
To view this page please follow the link below:
Therapeutic Goods Administration: COVID-19 vaccines
CVU registrations close Tuesday December 1, 2020
Our first virtual Clinical Vaccinology Update (CVU) will be held on December 7, 2020 and will host various local and international presenters. The topics covered include COVID-19 vaccines, influenza, vaccine safety, and vaccine communication.
Registrations to attend are closing soon. Be sure to purchase your tickets by tomorrow December 1, 2020 so you don't miss out!
Tickets can be purchased by heading to our Event page
Your unique webinar link will be sent to out via email in the coming days so please look out for it.
Aljazeera: COVID-19 vaccines explained in maps and charts
The following article gives an overview of the various vaccine platforms being utilised to develop a COVID-19 vaccine, and outlines which vaccines are currenly in human trials.
To read more follow the link below.:
Aljazeera: COVID-19 vaccines explained in maps and charts
NCIRS webinar- SARS-CoV-2 vaccine development: Is a finish line in sight?
The National Centre for Immunisation Research and Surveillance (NCIRS), have recently hosted a webinar titled: SARS-CoV-2 vaccine development: Is a finish line in sight?
Associate Professor Chris Blythe and Dr Melanie Saville present the current COVID-19 vaccine development landscape, Coalition for Epidemic Preparedness Innovations (CEPI) and the COVAX response, and the ethical and logistical implications of global vaccine implementation.
To view this webinar please follow the link below:
NCIRS- SARS-CoV-2 vaccine development: Is a finish line in sight?
MMWR: The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020
Once a COVID-19 vaccine has been approved for use, it is expected that the initial supply will be limited. The Advisory Committee on Immunization Practices (ACIP) in the United States, has published it's approach for recommending and allocating COVID-19 vaccines to the American population. In addition to scientific data, decisions on the allocation of COVID-19 vaccines will be based around 4 ethical principles. These include: the need to maximise benefit and minimise harm, promote justice, mitigate health inequities and promote transparency.
To read the article in full, please see the link below:
Complete program for the December CVU now available
The next Clinical Vaccinology Update will be held virtually on December 7.
We are excited to welcome both local and international presenters covering a wide range of immunisation topics including COVID-19 vaccine updates, vaccine communication and confidence, influenza vaccines, Zostavax® and measles.
To view the complete program and to purchase tickets, please follow the link below to our Events page:
क्लिनिकल वैक्सीनोलॉजी अपडेट: 7 दिसंबर 2020
Final episode of COVID19 Road to a vaccine: Professor Walter Orenstein
In the final episode of this podcast series our host, Associate Professor Nigel Crawford, speaks with Professor Walter Orenstein. Dr Orenstein is a Professor of Medicine, Epidemiology, Global Health and Paediatrics at Emory University; Associate Director of the Emory Vaccine Center and the Director of Emory Vaccine Policy and Development. An expert in vaccinology, Dr Orenstein has worked at the US Centers for Disease Control and Prevention, Director of the United States Immunisation Program and is a current member of several WHO groups. Further to this he is the co-editor of the vaccine textbook, Plotkin’s Vaccines, 7वां edition. In this episode they discuss:
- Lessons that can be learnt from Plotkin’s Vaccines in the setting of the SARS-CoV-2 pandemic and development of vaccines
- Recent press releases showing promising early results from two mRNA COVID-19 vaccine candidates developed by Pfizer/BioNTech and Moderna
- The critical role of ongoing monitoring for safety and effectiveness of vaccines once they are in use
- The likely highest priority groups when vaccines do become available
- The role of children in SARS-CoV-2 transmission and whether or not they need to be vaccinated
- The importance of a correlate of protection in SARS-CoV-2 vaccines
- The need to monitor for vaccine associated enhanced disease (VAED)
- The importance of immunisation providers supporting reports of adverse events following immunisation (AEFI)
- The importance of communication in supporting vaccine acceptance and uptake
- Key next steps on the road to a COVID-19 vaccine: a better understanding of how many doses are required and when, a prioritisation process so the vaccines can be used most effectively (with a clear allocation system); and communicating to the public that social distancing and wearing a mask will be ongoing for some time as a level of normality won’t be reached immediately, even with the exciting new efficacious COVID-19 vaccines
लिंक:
- Plotkin’s Vaccines, 7वां ed
- Pfizer/BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints
- Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study
आप यहां एपिसोड सुन सकते हैं:
The Lancet - Emergency use authorisation for COVID-19 vaccines: lessons from Ebola
In order to increase public acceptance of an emergency use authorisation for COVID-19 vaccines, the following article in The Lancet suggests that lessons can be learnt from previous experiences with Ebola virus vaccines in Guinea and the Democratic Republic on the Congo.
Emergency use authorisation allows the public to access promising medicinal products prior to licensing and registration. In the setting of a public health emergency, their use may be ethically justified if certain conditions are met.
By having a transparent evaluation process, ensuring that it meets a favourable benefit-risk ratio based on quality and safety data, and having an accountable system of regulatory oversight and monitoring, the ethical quality and overall acceptance of a COVID-19 vaccine can be improved.
अधिक पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
The Lancet - Emergency use authorisation for COVID-19 vaccines: lessons from Ebola